Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma

The discovery of the BRAF(V600E) mutation led to the development of vemurafenib (PLX4032), a selective BRAF inhibitor specific to the kinase, for the treatment of metastatic melanomas. However, initial success of the drug was dampened by the development of acquired resistance. Melanoma was shown to...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Xian Yang, Singh, Alamdeep, Osman, Narin, Piva, Terrence J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536016/
https://www.ncbi.nlm.nih.gov/pubmed/28708099
http://dx.doi.org/10.3390/ijms18071527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536016/
https://www.ncbi.nlm.nih.gov/pubmed/28708099
http://dx.doi.org/10.3390/ijms18071527

Ejemplares similares